Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ADGRE4P Biologics Sequence Review Report 2026: Putative adhesion G protein-coupled receptor E4P Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADGRE4P protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADGRG3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor G3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADGRG3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADGRG5 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor G5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADGRG5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ACKR4 Biologics Sequence Review Report 2026: Atypical chemokine receptor 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ACKR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ACKR1 Biologics Sequence Review Report 2026: Atypical chemokine receptor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ACKR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
VCAM1 Biologics Sequence Review Report 2026: Vascular cell adhesion protein 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of VCAM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ADGRA1 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor A1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of ADGRA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP2 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFAIP3 Biologics Sequence Review Report 2026: Tumor necrosis factor alpha-induced protein 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TNFAIP3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SEMA7A Biologics Sequence Review Report 2026: Semaphorin-7A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA7A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TGFBI Biologics Sequence Review Report 2026: Transforming growth factor-beta-induced protein ig-h3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of TGFBI protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
SEMA4F Biologics Sequence Review Report 2026: Semaphorin-4F Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4F protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.